Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924374 | 0.83 | LPAR3 (0.52) | CYP2D6CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL26334857 | 0.83 | CYP2D6 (0.39) | CYP2D6CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL12914742 | 0.82 | SAT1 (0.57) | SAT1CYP1A2LPAR3LPAR2LPAR1 | |
| SCHEMBL26334858 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL26334849 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL26334850 | 0.82 | CYP2D6 (0.42) | CYP2D6CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL17327639 | 0.81 | LPAR3 (0.37) | CYP2D6CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL16815002 | 0.80 | LPAR3 (0.56) | SAT1LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL16815019 | 0.80 | LPAR3 (0.56) | SAT1LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL16815020 | 0.80 | LPAR3 (0.56) | SAT1LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167441-A1 | Segmented Nucleic Acids | ZHONG MINGHONG (US) | 2023-06-01 | — | — | US | disclosed |
| US-20150209440-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140296322-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140037573-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130236986-A1 | METHODS OF SEPARATING NUCLEIC ACID POLYMER CONJUGATES | CERULEAN PHARMA INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120302622-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296322-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CD44, DIS3, POLN | SAT1 3944/4885CYP2D6 4285/4885CYP1A2 4735/4885 |
| US-20140037573-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | SAT1 3806/4885CYP2D6 4308/4885CYP1A2 4681/4885 |
| US-20120302622-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | SAT1 3806/4885CYP2D6 4308/4885CYP1A2 4681/4885 |
| US-20150209440-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CD44, DIS3, POLN | SAT1 3944/4885CYP2D6 4285/4885CYP1A2 4735/4885 |
| US-20120225129-A1 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | SYNCRIP, EXOSC5, EXOSC9 | SAT1 3806/4885CYP2D6 4308/4885CYP1A2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.